Market Research Logo

Hepatitis Therapeutics Market Analysis By Disease Type (Hepatitis A, B, C) By Region (North America, Europe, Asia Pacific, Latin America, MEA), And Segment Forecasts, 2014 - 2025

Hepatitis Therapeutics Market Analysis By Disease Type (Hepatitis A, B, C) By Region (North America, Europe, Asia Pacific, Latin America, MEA), And Segment Forecasts, 2014 - 2025

The global hepatitis therapeutics market is expected to reach USD 25.8 billion by 2025 according to a new report by Grand View Research, Inc. The key factors driving market growth include the rising number of infected population, growing consumption of alcohol & drugs, increase in global geriatric population, and improvement in access to hepatitis medicines.

Hepatitis is generally classified into two types based on the duration for which the patient suffers. If the condition lasts for less than six months, then it is classified as acute, when the condition persists for more than six months, then it is a case of chronic hepatitis.The population at a greater risk of hepatitis include people with HIV infection & HCV-infected sexual partners, who inject drugs & use intranasal drugs, recipients of infected blood products, and other population groups who live in unhygienic conditions.

According to the WHO, globally around 400 million people are infected with at least one form of hepatitis and every year nearly 1.4 people die due to the condition. Various government and private agencies are actively involved in the vaccination drive to prevent hepatitis. Hepatitis C leads to more serious complications compared to hepatitis A and B. As per WHO estimates, nearly 150 million are impacted by hepatitis C infection globally. Moreover, a significant number of hepatitis C patients develop liver cancer or liver cirrhosis and nearly 700,000 people die due to hepatitis C infection & associated conditions.

Further Key Findings From the Report Suggest:

Due to very high prevalence of target disease coupled with subsequent increase in the treatment rate Hepatitis C accounted for the majority market share of 75.6% in 2016

In 2016, North America held the largest share of nearly 42.9%. The key factors attributed to the regions high share include high patient awareness levels and the presence of advanced healthcare infrastructure.

Asia Pacific is anticipated to witness the maximum growth with a CAGR of 5.8% over the forecast period. High economic development coupled with rapidly increasing healthcare expenditure are amongst key factors attributing to the regions high growth rate.

Key players include Gilead, Merck & Co. Inc., Johnson & Johnson, Bristol-Myers Squibb Company, and AbbVie Inc.


Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
1.3. List of Data Sources
Chapter 2. Executive Summary
2.1. Market Snapshot
Chapter 3. Hepatitis Therapeutics Market Variables, Trends& Scope
3.1. Market Segmentation
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.2. Market restraint analysis
3.3. Key Opportunities Prioritized
3.4. Industry Analysis - Porter's
3.5. Hepatitis Therapeutics Market-SWOT Analysis, By Factor (political & legal, economic and technological), 2015
Chapter 4. Hepatitis Therapeutics Market: Disease Type Estimates & Trend Analysis
4.1. Hepatitis Therapeutics Market Share by Disease Type, 2015 & 2025 (USD Million)
4.2. Hepatitis A
4.2.1. Market estimates and forecast, 2014 - 2025 (USD Million)
4.3. Hepatitis B
4.3.1. Market estimates and forecast, 2014 - 2025 (USD Million)
4.4. Hepatitis C
4.4.1. Market estimates and forecast, 2014 - 2025 (USD Million)
4.5. Others
4.5.1. Market estimates and forecast, 2014 - 2025 (USD Million)
Chapter 5. Hepatitis Therapeutics Market: Regional Outlook
5.1. Hepatitis Therapeutics Market share by region, 2015 & 2025 (USD Million)
5.2. North America
5.2.1. Market estimates and forecast, 2014 - 2025 (USD Million)
5.2.2. Market estimates and forecast by disease type, 2014 - 2025 (USD Million)
5.2.3. U.S.
5.2.3.1. Market estimates and forecast, 2014 - 2025 (USD Million)
5.2.3.2. Market estimates and forecast by disease type, 2014 - 2025 (USD Million)
5.2.4. Canada
5.2.4.1. Market estimates and forecast, 2014 - 2025 (USD Million)
5.2.4.2. Market estimates and forecast by disease type, 2014 - 2025 (USD Million)
5.3. Europe
5.3.1. Market estimates and forecast, 2014 - 2025 (USD Million)
5.3.2. Market estimates and forecast by disease type, 2014 - 2025 (USD Million)
5.3.3. Germany
5.3.3.1. Market estimates and forecast, 2014 - 2025 (USD Million)
5.3.3.2. Market estimates and forecast by disease type, 2014 - 2025 (USD Million)
5.3.4. UK
5.3.4.1. Market estimates and forecast, 2014 - 2025 (USD Million)
5.3.4.2. Market estimates and forecast by disease type, 2014 - 2025 (USD Million)
5.4. Asia Pacific
5.4.1. Market estimates and forecast, 2014 - 2025 (USD Million)
5.4.2. Market estimates and forecast by disease type, 2014 - 2025 (USD Million)
5.4.3. China
5.4.3.1. Market estimates and forecast, 2014 - 2025 (USD Million)
5.4.3.2. Market estimates and forecast by disease type, 2014 - 2025 (USD Million)
5.4.4. Japan
5.4.4.1. Market estimates and forecast, 2014 - 2025 (USD Million)
5.4.4.2. Market estimates and forecast by disease type, 2014 - 2025 (USD Million)
5.5. Latin America
5.5.1. Market estimates and forecast, 2014 - 2025 (USD Million)
5.5.2. Market estimates and forecast by disease type, 2014 - 2025 (USD Million)
5.5.3. Brazil
5.5.3.1. Market estimates and forecast, 2014 - 2025 (USD Million)
5.5.3.2. Market estimates and forecast by disease type, 2014 - 2025 (USD Million)
5.5.4. Mexico
5.5.4.1. Market estimates and forecast, 2014 - 2025 (USD Million)
5.5.4.2. Market estimates and forecast by disease type, 2014 - 2025 (USD Million)
5.6. Middle East & Africa
5.6.1. Market estimates and forecast, 2014 - 2025 (USD Million)
5.6.2. Market estimates and forecast by disease type, 2014 - 2025 (USD Million)
5.6.3. South Africa
5.6.3.1. Market estimates and forecast, 2014 - 2025 (USD Million)
5.6.3.2. Market estimates and forecast by disease type, 2014 - 2025 (USD Million)
Chapter 6. Competitive Landscape
6.1. Strategic Framework
6.2. Gilead Lifesciences
6.2.1. Company overview
6.2.2. Financial performance
6.2.3. Product benchmarking
6.2.4. Strategic initiatives
6.3. Bristol-Myers Squibb Co
6.3.1. Company overview
6.3.2. Financial performance
6.3.3. Product benchmarking
6.3.4. Strategic initiatives
6.4. Biocon
6.4.1. Company overview
6.4.2. Financial performance
6.4.3. Product benchmarking
6.4.4. Strategic initiatives
6.5. AbbVie
6.5.1. Company overview
6.5.2. Financial performance
6.5.3. Product benchmarking
6.5.4. Strategic initiatives
6.6. Merck & Co., Inc.,
6.6.1. Company overview
6.6.2. Financial performance
6.6.3. Product benchmarking
6.6.4. Strategic initiatives
6.7. Johnson & Johnson
6.7.1. Company overview
6.7.2. Financial performance
6.7.3. Product benchmarking
6.7.4. Strategic initiatives
List of Tables
TABLE 1 hepatitis therapeutics market estimates and forecast by disease type, 2014 - 2025 (USD Million)
TABLE 2 North America hepatitis therapeutics market estimates and forecast by disease type, 2014 - 2025 (USD Million)
TABLE 3 U.S. hepatitis therapeutics market estimates and forecast by disease type, 2014 - 2025 (USD Million)
TABLE 4 Canada hepatitis therapeutics market estimates and forecast by disease type, 2014 - 2025 (USD Million)
TABLE 5 Europe hepatitis therapeutics market estimates and forecast by disease type, 2014 - 2025 (USD Million)
TABLE 6 Germany hepatitis therapeutics market estimates and forecast by disease type, 2014 - 2025 (USD Million)
TABLE 7 UK hepatitis therapeutics market estimates and forecast by disease type, 2014 - 2025 (USD Million)
TABLE 8 Asia Pacific hepatitis therapeutics market estimates and forecast by disease type, 2014 - 2025 (USD Million)
TABLE 9 China hepatitis therapeutics market estimates and forecast by disease type, 2014 - 2025 (USD Million)
TABLE 10 Japan hepatitis therapeutics market estimates and forecast by disease type, 2014 - 2025 (USD Million)
TABLE 11 Latin America hepatitis therapeutics market estimates and forecast by disease type, 2014 - 2025 (USD Million)
TABLE 12 Brazil hepatitis therapeutics market estimates and forecast by disease type, 2014 - 2025 (USD Million)
TABLE 13 Mexico hepatitis therapeutics market estimates and forecast by disease type, 2014 - 2025 (USD Million)
TABLE 14 Middle East & Africa hepatitis therapeutics market estimates and forecast by disease type, 2014 - 2025 (USD Million)
TABLE 15 South Africa hepatitis therapeutics market estimates and forecast by disease type, 2014 - 2025 (USD Million)
List of Figures
FIG. 1 Market research process
FIG. 2 Information procurement
FIG. 3 Primary research pattern
FIG. 4 Market summary
FIG. 5 Market trends & outlook
FIG. 6 Market segmentation & scope
FIG. 7 Market driver relevance analysis (Current & future impact)
FIG. 8 Market restraint relevance analysis (Current & future impact)
FIG. 9 Key Opportunity Priorities
FIG. 10 SWOT Analysis, By Factor (political & legal, economic and technological)
FIG. 11 Porter’s Five Forces Analysis
FIG. 12 Hepatitis therapeutics market, Heat Map Analysis
FIG. 13 Hepatitis therapeutics market product outlook key takeaways
FIG. 14 Hepatitis therapeutics market: Disease type movement analysis
FIG. 15 Hepatitis A market, 2014 - 2025 (USD Million)
FIG. 16 Hepatitis B market, 2014 - 2025 (USD Million)
FIG. 17 Hepatitis C market, 2014 - 2025 (USD Million)
FIG. 18 Other hepatitis therapeutics market, 2014 - 2025 (USD Million)
FIG. 19 Regional outlook, 2015 & 2024
FIG. 20 North America hepatitis therapeutics market estimates and forecasts, 2014 - 2025 (USD Million)
FIG. 21 U.S. hepatitis therapeutics market estimates and forecasts, 2014 - 2025 (USD Million)
FIG. 22 Canada hepatitis therapeutics market estimates and forecasts, 2014 - 2025 (USD Million)
FIG. 23 Europe hepatitis therapeutics market estimates and forecasts, 2014 - 2025 (USD Million)
FIG. 24 Germany hepatitis therapeutics market estimates and forecasts, 2014 - 2025 (USD Million)
FIG. 25 UK hepatitis therapeutics market estimates and forecasts, 2014 - 2025 (USD Million)
FIG. 26 Asia Pacific hepatitis therapeutics market estimates and forecasts, 2013 - 2024 (USD Million)
FIG. 27 China hepatitis therapeutics market estimates and forecasts, 2013 - 2024 (USD Million)
FIG. 28 Japan hepatitis therapeutics market estimates and forecasts, 2013 - 2024 (USD Million)
FIG. 29 Latin America hepatitis therapeutics market estimates and forecasts, 2013 - 2024 (USD Million)
FIG. 30 Brazil hepatitis therapeutics market estimates and forecasts, 2013 - 2024 (USD Million)
FIG. 31 Mexico hepatitis therapeutics market estimates and forecasts, 2013 - 2024 (USD Million)
FIG. 32 MEA hepatitis therapeutics market estimates and forecasts, 2013 - 2024 (USD Million)
FIG. 33 South Africa hepatitis therapeutics market estimates and forecasts, 2013 - 2024 (USD Million)

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report